产品名称

利伐沙班(Rivaroxaban)

一般描述

Rivaroxaban(利伐沙班) is an orally bioavailable oxazolidinone derivative and direct inhibitor of  the coagulation factor Xa with anticoagulant activity.

别 称

5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide; BAY59-7939;Xarelto;

纯 度

≥99%(HPLC)

CAS NO.

366789-02-8

分子式

C¹⁹H¹⁸ClN³O⁵S

分子量

435.879

适用范围

生物试剂，适用于细胞培养等

l  理化信息

外 观

白色至类白色固体

溶解性(25℃)

DMSO

≥50mg/mL

乙醇

Insoluble

水

Insoluble

l  生物学信息

生物活性/药理作用

Rivaroxaban is an anticoagulant which binds directly to factor Xa.Thereafter, it effectively blocks the amplification of  the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.

Rivaroxaban is an orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban  selectively binds to both free factor Xa and factor Xa bound in the  prothrombinase complex. This interferes with the conversion of prothrombin  (factor II) to thrombin and eventually prevents the formation of cross-ed fibrin clots. Rivaroxaban does not affect existing thrombin levels.

l  包装与存储

包 装

250mg; 1g

存储温度

0-5℃

l  注意事项及免责声明

本产品仅用于实验研究，不得作为药物使用，不得用于家用或其它用途。

l  参考文献

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.   https://www.ncbi.nlm.nih.gov